Compare Incyte Corporation (INCY) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs SkyWest Inc — how do they compare? Incyte Corporation trades at $117.76 (market cap $23.11B), while SkyWest Inc trades at $98.54 (market cap $3.94B). The key difference: Incyte Corporation is far larger — about 5.9× SkyWest Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, SkyWest Inc nearer its low. Which is the better fit depends on your goals.
| INCY | SKYW | |
|---|---|---|
Market Cap | $23.11B | $3.94B |
Sector | Health | Technology |
52-Week High | $118.52 | $123.72 |
52-Week Low | $67.38 | $78.40 |
Enterprise Value | $19.13B | $5.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
SkyWest (SKYW) trades at $99.34, up 2.17% today, with a neutral technical signal but bullish moving averages. The stock shows strong profitability with a 10.42% net margin and attractive valuation at a P/E of 9.32. Recent earnings have been mixed, beating in Q1 2026 but missing in Q4 2025, with Q2 2026 results pending. Analyst consensus is bullish with a $109.33 price target, though news highlights concerns over rising fuel costs impacting airline profits.
The outlook for SKYW is cautiously optimistic, supported by solid fundamentals and analyst buy ratings, but faces headwinds from volatile fuel expenses and competitive pressures. Upside potential exists if the company maintains earnings momentum and manages cost inflation, while downside risks include economic sensitivity and operational challenges in the airline industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
